Description

Bausch Health: Solta’s Global Expansion Playbook Is Working—But Can China’s Slowdown Be Offset?

Bausch Health Companies Inc. delivered its tenth consecutive quarter of revenue and adjusted EBITDA growth in the third quarter of 2025, driven by growth across multiple business segments. The company reported a 7% year-over-year increase in revenue, reaching $2.681 billion, and an 8% rise in adjusted EBITDA to $986 million. These results exclude Bausch + Lomb, which is sometimes separately highlighted due to the company’s strategic positioning. One key area of strength was in the Solta Medical segment, which saw a 25% increase in revenue to $140 million, primarily driven by demand in the Asia Pacific region, particularly South Korea. The Salix segment also performed well with a 12% revenue increase to $716 million, attributed to the growth of Xifaxan, driven by enhanced marketing and operational strategies such as AI-driven customer insights and direct-to-consumer advertising. Salix’s growth was partially offset by unfavorable pricing effects in some channels.